Blood Component Removal

• 

  Subject Areas on Research

  • A large university medical center delivery system for therapeutic apheresis services. 
  • American Society for Apheresis white paper: considerations for medical staff apheresis medicine physician credentialing and privileging. 
  • Anticoagulation techniques in apheresis: from heparin to citrate and beyond. 
  • Apheresis and the thrombotic thrombocytopenic purpura syndrome: current advances in diagnosis, pathophysiology, and management. 
  • Apheresis for collection of Ebola convalescent plasma in Liberia. 
  • Apheresis to Mitigate Atherosclerotic Vascular Disease. 
  • Apheresis. New opportunities. 
  • Bedside Allogeneic Erythrocyte Washing with a Cell Saver to Remove Cytokines, Chemokines, and Cell-derived Microvesicles. 
  • Bye-bye TRALI: by understanding and innovation. 
  • Category IV indications for therapeutic apheresis: ASFA fourth special issue. 
  • Current patterns of use in therapeutic apheresis: a metropolitan center experience. 
  • Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. 
  • Extended storage of AS-1 and AS-3 leukoreduced red blood cells for 15 days after deglycerolization and resuspension in AS-3 using an automated closed system. 
  • Frequency of rare, serious donor reactions: International perspective. 
  • G-CSF and peripheral blood progenitor cells. 
  • Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. 
  • Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. 
  • Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. 
  • Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. 
  • Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. 
  • Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. 
  • How we approach an apheresis request for a Category III, Category IV, or noncategorized indication. 
  • How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures. 
  • Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner. 
  • Impact of transfusion of autologous 7- versus 42-day-old AS-3 red blood cells on tissue oxygenation and the microcirculation in healthy volunteers. 
  • In Vitro Evaluation of the Fresenius Kabi CATSmart Autotransfusion System. 
  • In vitro and numerical simulation of blood removal from cerebrospinal fluid: comparison of lumbar drain to Neurapheresis therapy. 
  • In vivo and in vitro characteristics of double units of RBCs collected by apheresis with a single in-line WBC-reduction filter. 
  • Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. 
  • Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. 
  • Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange. 
  • Intramyocardial, autologous CD34+ cell therapy for refractory angina. 
  • Large-scale mobilization and isolation of CD34+ cells from normal donors. 
  • Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. 
  • Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. 
  • Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. 
  • Novel Dual Lumen Catheter and Filtration Device for Removal of Subarachnoid hemorrhage: First Case Report. 
  • Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. 
  • Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. 
  • Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. 
  • Quantitation of residual white cells in filtered blood components by polymerase chain reaction amplification of HLA DQ-A DNA. 
  • Storage characteristics of multiple-donor pooled red blood cells compared to single-donor red blood cell units. 
  • Strategies to Aid Identification of Apheresis PowerFlow Ports: A Case Report. 
  • The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation. 
  • The new approach to assignment of ASFA categories--introduction to the fourth special issue: clinical applications of therapeutic apheresis. 
  • The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends. 
  • The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network. 
  • The top clinical trial opportunities in therapeutic apheresis and neurology. 
  • Therapeutic apheresis before and after kidney transplantation. 
  • Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine. 
  • Therapeutic approaches to the treatment of rheumatoid disease. 
  • Therapeutic white blood cell and platelet depletions using the spectra OPTIA system continuous mononuclear cell protocol. 
  • Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. 
  • Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. 
  • Trends in platelet distributions from 2008 to 2017: a survey of twelve national and regional blood collectors. 
  • United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. 
  • Update on multi-center clinical trials in the United States. 
  • Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.